Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

14.97USD
6:32pm BST
Change (% chg)

$-0.14 (-0.93%)
Prev Close
$15.11
Open
$15.16
Day's High
$15.19
Day's Low
$14.55
Volume
97,870
Avg. Vol
220,444
52-wk High
$43.85
52-wk Low
$14.31

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics To Initiate Tab-cel FDA Biologics License Application Submission Next Year
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PLAN TO INITIATE TAB-CEL® FDA BIOLOGICS LICENSE APPLICATION SUBMISSION NEXT YEAR.ATARA BIOTHERAPEUTICS - PLANS TO INITIATE A TAB-CEL BIOLOGICS LICENSE APPLICATION SUBMISSION FOR PATIENTS WITH EBV+ PTLD IN H2 2020.ATARA BIOTHERAPEUTICS - DOES NOT EXPECT TO DISCLOSE INTERIM TOP-LINE EBV+ PTLD RESULTS UNTIL AFTER ACCEPTANCE OF FDA BLA FILING.  Full Article

Atara Biotherapeutics Intends To Provide Update On Discussions With FDA Regarding Development Of Tab-Cel
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS - INTENDS TO PROVIDE UPDATE RELATED TO ONGOING DISCUSSIONS WITH U.S. FDA REGARDING DEVELOPMENT OF TAB-CEL(REG).ATARA BIOTHERAPEUTICS - BASED ON PRELIMINARY FDA FEEDBACK, PLANS TO COMBINE TWO ONGOING TAB-CEL((REG))PHASE 3 CLINICAL STUDIES (MATCH AND ALLELE).ATARA BIOTHERAPEUTICS INC - DOES NOT EXPECT TO CHANGE PRIMARY ENDPOINT FOR TWO COHORTS OF COMBINED STUDY.  Full Article

Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer
Tuesday, 28 May 2019 

May 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS.ATARA BIOTHERAPEUTICS INC - TOUCHON WAS MOST RECENTLY AT NOVARTIS ONCOLOGY AS GLOBAL HEAD, CELL & GENE AND MEMBER OF ONCOLOGY EXECUTIVE COMMITTEE.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER STEPPED DOWN FROM HIS ROLE AS PRESIDENT, CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - DIETMAR BERGER, ATARA'S GLOBAL HEAD OF RESEARCH AND DEVELOPMENT, HAS RESIGNED.  Full Article

Atara Biotherapeutics Reports Q1 Loss Per Share Of $1.44
Thursday, 9 May 2019 

May 9 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q1 LOSS PER SHARE $1.44.Q1 EARNINGS PER SHARE ESTIMATE $-1.51 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 TOTALED $237.5 MILLION.ATARA BIOTHERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS TO MID-2020.  Full Article

Atara Biotherapeutics CEO To Step Down; Board Initiates Search For Successor
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PLANNED CHIEF EXECUTIVE OFFICER TRANSITION.ATARA BIOTHERAPEUTICS INC - CIECHANOVER WILL REMAIN IN HIS ROLE AS PRESIDENT AND CEO UNTIL EARLIER OF APPOINTMENT OF HIS SUCCESSOR OR JUNE 30, 2019.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER PLANS TO STEP DOWN AS COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - BOARD OF DIRECTORS HAS INITIATED A SEARCH FOR ISAAC CIECHANOVER'S SUCCESSOR.  Full Article

Atara Biotherapeutics Reports Q3 Loss Per Share Of $1.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q3 LOSS PER SHARE $1.29.Q3 EARNINGS PER SHARE VIEW $-1.13 -- THOMSON REUTERS I/B/E/S.ATARA BIOTHERAPEUTICS- CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS AS OF SEPT 30 WAS $364.5 MILLION, SUFFIECIENT TO FUND PLANNED OPERATION TO MID-2020.ATARA BIOTHERAPEUTICS - INITIAL RESULTS FROM OFF-THE-SHELF, ALLOGENEIC ATA188 MULTIPLE SCLEROSIS PROGRAM ARE ANTICIPATED IN FIRST HALF OF 2019.  Full Article

Atara Biotherapeutics prices public offering of stock at $35 per share​
Thursday, 1 Mar 2018 

Feb 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $35.00 PER SHARE​.  Full Article

Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS SHARES OF COMMON STOCK.  Full Article

Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.QTRLY LOSS PER SHARE $1.15.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2017 TOTALED $166.1 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Atara Biotherapeutics Says CFO Intends To Retire In April 2018
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018.ATARA BIOTHERAPEUTICS INC - ‍JOHN MCGRATH, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INTENDS TO RETIRE FROM CO AS OF APRIL 27, 2018​.  Full Article

BRIEF-Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer

* ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS